Schizophrenia Clinical Trials in Garden Grove, California
12 recruitingGarden Grove, California
Showing 1–12 of 12 trials
Recruiting
Phase 4
A Study to Evaluate the Effect of KarXT on Urological Safety
Schizophrenia
Bristol-Myers Squibb60 enrolled14 locationsNCT07221877
Recruiting
Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled73 locationsNCT06894212
Recruiting
Phase 2
A Study of Brenipatide in Adult Participants With Schizophrenia
Schizophrenia
Eli Lilly and Company450 enrolled102 locationsNCT07410507
Recruiting
Phase 3
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences560 enrolled17 locationsNCT07227818
Recruiting
Phase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences800 enrolled53 locationsNCT07114874
Recruiting
Phase 3
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences284 enrolled11 locationsNCT07105098
Recruiting
Phase 3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company280 enrolled175 locationsNCT05304767
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
Schizophrenia
MapLight Therapeutics300 enrolled25 locationsNCT07038876
Recruiting
Phase 2
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
Schizophrenia
AbbVie268 enrolled7 locationsNCT07145918
Recruiting
Phase 2
Study of ALTO-101 in Patients With Schizophrenia
Cognitive ImpairmentSchizophrenia
Alto Neuroscience82 enrolled14 locationsNCT06502964
Recruiting
Phase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
SchizophreniaAutism Spectrum DisorderBipolar Disorder
Intra-Cellular Therapies, Inc.500 enrolled50 locationsNCT06229210
Recruiting
Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Schizophrenia
Reviva Pharmaceuticals690 enrolled18 locationsNCT05184335